


GW1100

09/19

ALTERNATE NAMES: Ethyl 4-[5-[(2-ethoxypyrimidin-5-yl)methyl]-2-[(4-fluorophenyl)methylsulfanyl]-4-oxypyrimidin-1-yl]benzoate; 1-(4-Ethoxycarbonylphenyl)-2-(4-fluorobenzylthio)-5-(2-ethoxy-5-pyrimidinylmethyl)-4-pyrimidinone; SB376752; Benzoic acid, 4-[5-[(2-ethoxy-5-pyrimidinyl)methyl]-2-[[4-(4-fluorophenyl)methyl]thio]-4-oxo-1(4H)-pyrimidinyl]-, ethyl ester

CATALOG #: B2905-5 5 mg
B2905-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₇H₂₅FN₄O₄S

MOLECULAR WEIGHT: 520.58

CAS NUMBER: 306974-70-9

APPEARANCE: A crystalline solid

PURITY: ≥95%

SOLUBILITY: ~2 mg/ml in DMSO
~5 mg/ml in DMF

DESCRIPTION: GW1100 is an antagonist for the free fatty acid receptor FFAR1 (GPR40). It inhibits GPR40-mediated Ca²⁺ elevations stimulated by GW 9508 (agonist for GPR40 and GPR120) and linoleic acid with pIC₅₀ values of 5.99 ± 0.03 and 5.99 ± 0.06 respectively. GW1100 reverses the potentiating effects of GW 9508 on glucose-stimulated insulin secretion in MIN6 mouse insulinoma cell line, at a concentration of 1 μM.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Briscoe, C.P., Peat, A.J., McKeown, S.C., et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: Identification of agonist and antagonist small molecules. *Br. J. Pharmacol.* 148(5), 619-628 (2006).

RELATED PRODUCTS:

GW 9508 (Cat. No. 2817)
 MEDICA 16 (Cat. No. B2508)
 GSK137647A (Cat. No. B1112)
 TUG-891 (Cat. No. B2285)
 Fasiglifam (TAK-875) (Cat. No. B1280)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**